Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:730.

  • 2.

    Moch H, Gasser T, Amin MB. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604614.

    • Search Google Scholar
    • Export Citation
  • 3.

    Leibovich BC, Lohse CM, Crispen PL. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183:13091315.

    • Search Google Scholar
    • Export Citation
  • 4.

    Choyke PL, Glenn GM, Walther MM. Hereditary renal cancers. Radiology 2003;226:3346.

  • 5.

    DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: Principles & Practice of Oncology, 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 6.

    Cancer Stat Fact: Kidney and Renal Pelvis Cancer. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html.

  • 7.

    Ficarra V, Schips L, Guille F. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 2005;104:968974.

    • Search Google Scholar
    • Export Citation
  • 8.

    Frank I, Blute ML, Leibovich BC. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005;173:18891892.

    • Search Google Scholar
    • Export Citation
  • 9.

    Zisman A, Pantuck AJ, Chao D. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 2001;166:5458.

    • Search Google Scholar
    • Export Citation
  • 10.

    Klatte T, Patard JJ, Goel RH. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol 2007;178:3540; discussion 40.

    • Search Google Scholar
    • Export Citation
  • 11.

    Lam JS, Klatte T, Patard JJ. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 2007;52:155162.

    • Search Google Scholar
    • Export Citation
  • 12.

    Minervini A, Lilas L, Minervini R, Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 2002;94:25902595.

    • Search Google Scholar
    • Export Citation
  • 13.

    Dall'Oglio MF, Antunes AA, Sarkis AS. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 2007;100:552555.

    • Search Google Scholar
    • Export Citation
  • 14.

    Dall'Oglio MF, Ribeiro-Filho LA, Antunes AA. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol 2007;178:425428; discussion 428.

    • Search Google Scholar
    • Export Citation
  • 15.

    Lam JS, Shvarts O, Said JW. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005;103:25172525.

    • Search Google Scholar
    • Export Citation
  • 16.

    Sengupta S, Lohse CM, Leibovich BC. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005;104:511520.

    • Search Google Scholar
    • Export Citation
  • 17.

    Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;51:203205.

  • 18.

    Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 2000;56:5862..

    • Search Google Scholar
    • Export Citation
  • 19.

    Shuch B, Vourganti S, Ricketts CJ. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 2014;32:431437.

    • Search Google Scholar
    • Export Citation
  • 20.

    Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology 2005;236:441450.

  • 21.

    Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993;150:11121114.

    • Search Google Scholar
    • Export Citation
  • 22.

    Miles D. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Cancer 2014;22:679687.

    • Search Google Scholar
    • Export Citation
  • 23.

    Sheth S, Scatarige JC, Horton KM. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics 2001;21 (Spec No):237254.

    • Search Google Scholar
    • Export Citation
  • 24.

    Hricak H, Demas BE, Williams RD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709715.

    • Search Google Scholar
    • Export Citation
  • 25.

    Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991;32:69118.

  • 26.

    Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996;48:692695.

    • Search Google Scholar
    • Export Citation
  • 27.

    Shannon BA, Cohen RJ, de Bruto H, Davies RJ. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol 2008;180:12571261; discussion 1261.

    • Search Google Scholar
    • Export Citation
  • 28.

    Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009;103:615619.

    • Search Google Scholar
    • Export Citation
  • 29.

    AJCC Cancer Staging Manual, Seventh Edition (2010), published by Springer Science+Business Media, LLC (SBM).

  • 30.

    Eble JN, Sauter G, Epstein JI, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.

    • Search Google Scholar
    • Export Citation
  • 31.

    Berger A, Brandina R, Atalla MA. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol 2009;182:21722176.

    • Search Google Scholar
    • Export Citation
  • 32.

    Burgess NA, Koo BC, Calvert RC. Randomized trial of laparoscopic v open nephrectomy. J Endourol 2007;21:610613.

  • 33.

    Chung SD, Huang KH, Lai MK. Long-term follow-up of hand-assisted laparoscopic radical nephrectomy for organ-confined renal cell carcinoma. Urology 2007;69:652655.

    • Search Google Scholar
    • Export Citation
  • 34.

    Gabr AH, Gdor Y, Strope SA. Patient and pathologic correlates with perioperative and long-term outcomes of laparoscopic radical nephrectomy. Urology 2009;74:635640.

    • Search Google Scholar
    • Export Citation
  • 35.

    Hemal AK, Kumar A. A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma. World J Urol 2009;27:8994.

    • Search Google Scholar
    • Export Citation
  • 36.

    Hemal AK, Kumar A, Kumar R. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007;177:862866.

    • Search Google Scholar
    • Export Citation
  • 37.

    Luo JH, Zhou FJ, Xie D. Analysis of long-term survival in patients with localized renal cell carcinoma: laparoscopic versus open radical nephrectomy. World J Urol 2010;28:289293.

    • Search Google Scholar
    • Export Citation
  • 38.

    Nambirajan T, Jeschke S, Al-Zahrani H. Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy. Urology 2004;64:919924.

    • Search Google Scholar
    • Export Citation
  • 39.

    Dash A, Vickers AJ, Schachter LR. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006;97:939945.

    • Search Google Scholar
    • Export Citation
  • 40.

    Lau WK, Blute ML, Weaver AL. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:12361242.

    • Search Google Scholar
    • Export Citation
  • 41.

    Lee CT, Katz J, Shi W. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000;163:730736.

  • 42.

    Leibovich BC, Blute ML, Cheville JC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:10661070.

    • Search Google Scholar
    • Export Citation
  • 43.

    Zini L, Perrotte P, Capitanio U. Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 2009;115:14651471.

  • 44.

    Lee HJ, Liss MA, Derweesh IH. Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors. Curr Opin Urol 2014;24:448452.

  • 45.

    Huang WC, Levey AS, Serio AM. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735740.

    • Search Google Scholar
    • Export Citation
  • 46.

    Go AS, Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:12961305.

    • Search Google Scholar
    • Export Citation
  • 47.

    Thompson RH, Boorjian SA, Lohse CM. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008;179:468471; discussion 472–463.

    • Search Google Scholar
    • Export Citation
  • 48.

    Weight CJ, Lieser G, Larson BT. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 2010;58:293298.

    • Search Google Scholar
    • Export Citation
  • 49.

    Weight CJ, Larson BT, Gao T. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 2010;76:631637.

    • Search Google Scholar
    • Export Citation
  • 50.

    Kim SP, Thompson RH, Boorjian SA. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012;188:5157.

    • Search Google Scholar
    • Export Citation
  • 51.

    Thompson RH, Siddiqui S, Lohse CM. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol 2009;182:26012606.

  • 52.

    Hollingsworth JM, Miller DC, Dunn RL. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology 2006;67:11751180.

    • Search Google Scholar
    • Export Citation
  • 53.

    Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 2006;7:3138.

  • 54.

    Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009;7:635642; quiz 643.

    • Search Google Scholar
    • Export Citation
  • 55.

    Tan HJ, Norton EC, Ye Z. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012;307:16291635.

    • Search Google Scholar
    • Export Citation
  • 56.

    Gill IS, Kavoussi LR, Lane BR. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:4146.

    • Search Google Scholar
    • Export Citation
  • 57.

    Gong EM, Orvieto MA, Zorn KC. Comparison of laparoscopic and open partial nephrectomy in clinical T1a renal tumors. J Endourol 2008;22:953957..

    • Search Google Scholar
    • Export Citation
  • 58.

    Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol 2010;183:473479.

  • 59.

    Funahashi Y, Hattori R, Yamamoto T. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol 2009;55:209215.

    • Search Google Scholar
    • Export Citation
  • 60.

    Blom JH, van Poppel H, Marechal JM. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:2834.

    • Search Google Scholar
    • Export Citation
  • 61.

    Blute ML, Leibovich BC, Cheville JC. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004;172:465469.

    • Search Google Scholar
    • Export Citation
  • 62.

    Capitanio U, Becker F, Blute ML. Lymph node dissection in renal cell carcinoma. Eur Urol 2011;60:12121220.

  • 63.

    Kuczyk M, Munch T, Machtens S. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 2002;89:517522.

    • Search Google Scholar
    • Export Citation
  • 64.

    Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005;48:252257.

    • Search Google Scholar
    • Export Citation
  • 65.

    O'Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 2009;181:20092017.

    • Search Google Scholar
    • Export Citation
  • 66.

    Lane BR, Tiong HY, Campbell SC. Management of the adrenal gland during partial nephrectomy. J Urol 2009;181:24302436; discussion 2436–2437.

    • Search Google Scholar
    • Export Citation
  • 67.

    Rais-Bahrami S, Guzzo TJ, Jarrett TW. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 2009;103:13551358.

    • Search Google Scholar
    • Export Citation
  • 68.

    Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol 2008;180:505508; discussion 508–509.

  • 69.

    Lane BR, Abouassaly R, Gao T. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116:31193126.

    • Search Google Scholar
    • Export Citation
  • 70.

    Bird VG, Carey RI, Ayyathurai R, Bird VY. Management of renal masses with laparoscopic-guided radiofrequency ablation versus laparoscopic partial nephrectomy. J Endourol 2009;23:8188.

    • Search Google Scholar
    • Export Citation
  • 71.

    Campbell SC, Novick AC, Belldegrun A. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:12711279.

  • 72.

    Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 2008;113:26712680.

  • 73.

    O'Malley RL, Berger AD, Kanofsky JA. A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. BJU Int 2007;99:395398.

    • Search Google Scholar
    • Export Citation
  • 74.

    Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes. Urology 2009;73:10771082.

    • Search Google Scholar
    • Export Citation
  • 75.

    Peycelon M, Hupertan V, Comperat E. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol 2009;181:3541.

    • Search Google Scholar
    • Export Citation
  • 76.

    Eggener SE, Yossepowitch O, Pettus JA. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006;24:31013106.

    • Search Google Scholar
    • Export Citation
  • 77.

    Stewart SB, Thompson RH, Psutka SP. Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance Guidelines. J Clin Oncol 2014.

    • Search Google Scholar
    • Export Citation
  • 78.

    Mucksavage P, Kutikov A, Magerfleisch L. Comparison of radiographical imaging modalities for measuring the diameter of renal masses: is there a sizeable difference? BJU Int 2011;108:E232236.

    • Search Google Scholar
    • Export Citation
  • 79.

    Smaldone MC, Fung C, Uzzo RG, Haas NB. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:765791.

    • Search Google Scholar
    • Export Citation
  • 80.

    Haas NB, Manola J, Uzzo RG. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:20082016.

    • Search Google Scholar
    • Export Citation
  • 81.

    Gill IS, Kavoussi LR, Lane BR. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:4146.

    • Search Google Scholar
    • Export Citation
  • 82.

    Herr HW. Partial nephrectomy for incidental renal cell carcinoma. Br J Urol 1994;74:431433.

  • 83.

    Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990;144:852857.

    • Search Google Scholar
    • Export Citation
  • 84.

    Adamy A, Chong KT, Chade D. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 2011;185:433438.

    • Search Google Scholar
    • Export Citation
  • 85.

    Lam JS, Shvarts O, Leppert JT. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466472; discussion 472; quiz 801.

    • Search Google Scholar
    • Export Citation
  • 86.

    Motzer RJ, Bacik J, Murphy BA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 87.

    Mekhail TM, Abou-Jawde RM, Boumerhi G. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832841.

    • Search Google Scholar
    • Export Citation
  • 88.

    Heng DY, Xie W, Regan MM. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:57945799.

    • Search Google Scholar
    • Export Citation
  • 89.

    Heng DY, Xie W, Regan MM. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141148.

    • Search Google Scholar
    • Export Citation
  • 90.

    Flanigan RC, Mickisch G, Sylvester R. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:10711076.

    • Search Google Scholar
    • Export Citation
  • 91.

    Flanigan RC, Salmon SE, Blumenstein BA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:16551659.

    • Search Google Scholar
    • Export Citation
  • 92.

    Mickisch GH, Garin A, van Poppel H. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966970.

    • Search Google Scholar
    • Export Citation
  • 93.

    Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol 2009;16:227233.

    • Search Google Scholar
    • Export Citation
  • 94.

    Culp SH, Tannir NM, Abel EJ. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:33783388.

    • Search Google Scholar
    • Export Citation
  • 95.

    Leibovich BC, Han KR, Bui MH. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:25662575.

    • Search Google Scholar
    • Export Citation
  • 96.

    Choueiri TK, Xie W, Kollmannsberger C. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:6066.

    • Search Google Scholar
    • Export Citation
  • 97.

    Rosenberg SA, Mule JJ, Spiess PJ. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:11691188.

    • Search Google Scholar
    • Export Citation
  • 98.

    Dutcher JP, Fisher RI, Weiss G. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157162.

    • Search Google Scholar
    • Export Citation
  • 99.

    Negrier S, Escudier B, Lasset C. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338:12721278.

    • Search Google Scholar
    • Export Citation
  • 100.

    Fyfe G, Fisher RI, Rosenberg SA. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688696.

    • Search Google Scholar
    • Export Citation
  • 101.

    McDermott DF, Regan MM, Clark JI. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133141.

    • Search Google Scholar
    • Export Citation
  • 102.

    Motzer RJ, Hutson TE, Tomczak P. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:35843590.

    • Search Google Scholar
    • Export Citation
  • 103.

    Yang JC, Sherry RM, Steinberg SM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:31273132.

    • Search Google Scholar
    • Export Citation
  • 104.

    Leibovich BC, Blute ML, Cheville JC. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:16631671.

    • Search Google Scholar
    • Export Citation
  • 105.

    Sternberg CN, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 106.

    Sternberg CN, Hawkins RE, Wagstaff J. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:12871296..

    • Search Google Scholar
    • Export Citation
  • 107.

    Motzer RJ, Hutson TE, Cella D. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722731.

  • 108.

    Motzer RJ, Hutson TE, McCann L. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370:17691770.

  • 109.

    Escudier BJ, Porta C, Bono P. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310 [abstract]. J Clin Oncol 2012;30(Suppl):Abstract CRA4502.

    • Search Google Scholar
    • Export Citation
  • 110.

    Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 111.

    Motzer RJ, Michaelson MD, Redman BG. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:1624.

    • Search Google Scholar
    • Export Citation
  • 112.

    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884896.

  • 113.

    Faivre S, Delbaldo C, Vera K. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:2535.

    • Search Google Scholar
    • Export Citation
  • 114.

    Gore ME, Szczylik C, Porta C. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 2015;113:1219.

    • Search Google Scholar
    • Export Citation
  • 115.

    Ruiz-Morales JM, Swierkowski M, Wells JC. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer 2016;65:102108.

    • Search Google Scholar
    • Export Citation
  • 116.

    Escudier B, Pluzanska A, Koralewski P. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 117.

    Rini BI, Choueiri TK, Elson P. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113:13091314.

  • 118.

    Rini BI, Halabi S, Rosenberg JE. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:21372143.

    • Search Google Scholar
    • Export Citation
  • 119.

    Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 120.

    Awada A, Hendlisz A, Gil T. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:18551861.

    • Search Google Scholar
    • Export Citation
  • 121.

    Clark JW, Eder JP, Ryan D. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:54725480.

    • Search Google Scholar
    • Export Citation
  • 122.

    Moore M, Hirte HW, Siu L. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:16881694.

    • Search Google Scholar
    • Export Citation
  • 123.

    Strumberg D, Richly H, Hilger RA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965972.

    • Search Google Scholar
    • Export Citation
  • 124.

    Wilhelm SM, Carter C, Tang L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:70997109.

    • Search Google Scholar
    • Export Citation
  • 125.

    Escudier B, Szczylik C, Hutson TE. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:12801289.

    • Search Google Scholar
    • Export Citation
  • 126.

    Hutson TE, Lesovoy V, Al-Shukri S. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:12871294.

    • Search Google Scholar
    • Export Citation
  • 127.

    Rini BI, Melichar B, Ueda T. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013;14:12331242.

    • Search Google Scholar
    • Export Citation
  • 128.

    Choueiri TK, Escudier B, Powles T. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:18141823.

  • 129.

    Choueiri TK, Escudier B, Powles T. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917927.

    • Search Google Scholar
    • Export Citation
  • 130.

    Motzer RJ, Escudier B, McDermott DF. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:18031813.

  • 131.

    Motzer RJ, Sharma P, McDermott DF. CheckMate 025 phase III trial: outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 498.

    • Search Google Scholar
    • Export Citation
  • 132.

    Cella D, Escudier B, Rini B. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013;108:15711578.

    • Search Google Scholar
    • Export Citation
  • 133.

    Escudier BJ, Motzer RJ, Sharma P. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 4509.

    • Search Google Scholar
    • Export Citation
  • 134.

    Motzer RJ, Hutson TE, Glen H. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:14731482.

    • Search Google Scholar
    • Export Citation
  • 135.

    Motzer RJ, Hutson TE, Ren M. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17:e45.

    • Search Google Scholar
    • Export Citation
  • 136.

    Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008;17:741748.

  • 137.

    Rini BI, Escudier B, Tomczak P. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:19311939.

    • Search Google Scholar
    • Export Citation
  • 138.

    Motzer RJ, Escudier B, Tomczak P. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552562.

    • Search Google Scholar
    • Export Citation
  • 139.

    Rini BI, de La Motte Rouge T, Harzstark AL. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer 2013;11:107114.

    • Search Google Scholar
    • Export Citation
  • 140.

    Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 141.

    Motzer RJ, Escudier B, Oudard S. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:42564265.

    • Search Google Scholar
    • Export Citation
  • 142.

    Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 143.

    Escudier B, Eisen T, Stadler WM. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:33123318.

    • Search Google Scholar
    • Export Citation
  • 144.

    Di Lorenzo G, Carteni G, Autorino R. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27:44694474.

    • Search Google Scholar
    • Export Citation
  • 145.

    Garcia JA, Hutson TE, Elson P. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010;116:53835390.

    • Search Google Scholar
    • Export Citation
  • 146.

    Motzer RJ, Rini BI, Bukowski RM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:25162524.

  • 147.

    Dudek AZ, Zolnierek J, Dham A. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:6167.

  • 148.

    Eichelberg C, Heuer R, Chun FK. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:13731378.

    • Search Google Scholar
    • Export Citation
  • 149.

    Sablin MP, Negrier S, Ravaud A. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:2934; discussion 34.

  • 150.

    Shepard DR, Rini BI, Garcia JA. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 5123.

    • Search Google Scholar
    • Export Citation
  • 151.

    Zimmermann K, Schmittel A, Steiner U. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350354.

    • Search Google Scholar
    • Export Citation
  • 152.

    Hainsworth JD, Rubin MS, Arrowsmith ER. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer 2013;11:270275.

    • Search Google Scholar
    • Export Citation
  • 153.

    Matrana MR, Duran C, Shetty A. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49:31693175.

    • Search Google Scholar
    • Export Citation
  • 154.

    Yang JC, Haworth L, Sherry RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427434.

    • Search Google Scholar
    • Export Citation
  • 155.

    Atkins MB, Hidalgo M, Stadler WM. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909918.

    • Search Google Scholar
    • Export Citation
  • 156.

    Hutson TE, Escudier B, Esteban E. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760767.

    • Search Google Scholar
    • Export Citation
  • 157.

    Hwang C, Heath EI. The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma. J Clin Oncol 2014;32:729734.

  • 158.

    Escudier B, Michaelson MD, Motzer RJ. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014;110:28212828.

    • Search Google Scholar
    • Export Citation
  • 159.

    Motzer RJ, Barrios CH, Kim TM. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:27652772.

    • Search Google Scholar
    • Export Citation
  • 160.

    Gore ME, Szczylik C, Porta C. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757763.

    • Search Google Scholar
    • Export Citation
  • 161.

    Choueiri TK, Plantade A, Elson P. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26:127131.

    • Search Google Scholar
    • Export Citation
  • 162.

    Tannir NM, Plimack E, Ng C. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62:10131019.

    • Search Google Scholar
    • Export Citation
  • 163.

    Plimack ER, Jonasch E, Bekele BN. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 4604.

    • Search Google Scholar
    • Export Citation
  • 164.

    Ravaud A, Oudard S, Gravis-Mescam G. First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) [abstract]. J Clin Oncol 2009;27(Suppl):Abstract 5146

    • Search Google Scholar
    • Export Citation
  • 165.

    Lee JL, Ahn JH, Lim HY. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23:21082114.

    • Search Google Scholar
    • Export Citation
  • 166.

    Molina AM, Feldman DR, Ginsberg MS. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012;30:335340. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20711632.

    • Search Google Scholar
    • Export Citation
  • 167.

    Shi HZ, Tian J, Li CL. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma. Asia Pac J Clin Oncol 2015;11:328333.

    • Search Google Scholar
    • Export Citation
  • 168.

    Armstrong AJ, Broderick S, Eisen T. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN) [abstract]. J Clin Oncol 2015;33(Suppl):Abstract 4507.

    • Search Google Scholar
    • Export Citation
  • 169.

    Tannir NM, Jonasch E, Albiges L. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 2016;69:866874.

    • Search Google Scholar
    • Export Citation
  • 170.

    Dutcher JP, de Souza P, McDermott D. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202209.

    • Search Google Scholar
    • Export Citation
  • 171.

    Venugopal B, Ansari J, Aitchison M. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol 2013;13:26.

  • 172.

    Blank CU, Bono P, Larkin JMG. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: subgroup analysis of REACT [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 402.

    • Search Google Scholar
    • Export Citation
  • 173.

    Larkin JM, Fisher RA, Pickering LM. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol 2011;29:e241242.

    • Search Google Scholar
    • Export Citation
  • 174.

    Koh Y, Kim JY, Lim HY. Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 4544.

    • Search Google Scholar
    • Export Citation
  • 175.

    Stadler WM, Figlin RA, McDermott DF. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:12721280.

    • Search Google Scholar
    • Export Citation
  • 176.

    Beck J, Procopio G, Bajetta E. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011;22:18121823.

    • Search Google Scholar
    • Export Citation
  • 177.

    Unnithan J, Vaziri S, Wood DP Jr. Characterization of type II papillary renal cell carcinoma and efficacy of sorafenib [abstract]. Presented at the 2008 Genitourinary Cancers Symposium; February 14–16, 2008; San Francisco, California. Abstract 409.

    • Search Google Scholar
    • Export Citation
  • 178.

    Buti S, Bersanelli M, Maines F. First-line pazopanib in non-clear cell renal carcinoma: the Italian retrospective multicenter PANORAMA study [abstract].J Clin Oncol 2016;34(Suppl):Abstract e16081.

    • Search Google Scholar
    • Export Citation
  • 179.

    Gordon MS, Hussey M, Nagle RB. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:57885793.

    • Search Google Scholar
    • Export Citation
  • 180.

    Irshad T, Olencki T, Zynger DL. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract e15158.

    • Search Google Scholar
    • Export Citation
  • 181.

    Chowdhury S, Matrana MR, Tsang C. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 2011;25:853869.

    • Search Google Scholar
    • Export Citation
  • 182.

    Patard JJ, Leray E, Rioux-Leclercq N. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:27632771.

    • Search Google Scholar
    • Export Citation
  • 183.

    Cheville JC, Lohse CM, Zincke H. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612624.

    • Search Google Scholar
    • Export Citation
  • 184.

    Cheville JC, Lohse CM, Zincke H. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004;28:435441.

    • Search Google Scholar
    • Export Citation
  • 185.

    Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 2012;17:4654.

    • Search Google Scholar
    • Export Citation
  • 186.

    Nanus DM, Garino A, Milowsky MI. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 187.

    Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011;28:15301533.

    • Search Google Scholar
    • Export Citation
  • 188.

    Haas NB, Lin X, Manola J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012;29:761767.

    • Search Google Scholar
    • Export Citation
  • 189.

    Richey SL, Ng C, Lim ZD. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011;29:e203205.

    • Search Google Scholar
    • Export Citation
  • 190.

    Tannir NM, Thall PF, Ng CS. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008;180:867872; discussion 872.

    • Search Google Scholar
    • Export Citation
  • 191.

    Stadler WM, Halabi S, Rini B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006;107:12731279.

    • Search Google Scholar
    • Export Citation
  • 192.

    Michaelson MD, McKay RR, Werner L. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer 2015;121:34353443.

    • Search Google Scholar
    • Export Citation
  • 193.

    Hakimi AA, Koi PT, Milhoua PM. Renal medullary carcinoma: the Bronx experience. Urology 2007;70:878882.

  • 194.

    Watanabe IC, Billis A, Guimaraes MS. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol 2007;20:914920.

  • 195.

    Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009;22(Suppl 2):S223.

  • 196.

    Tokuda N, Naito S, Matsuzaki O. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 2006;176:4043; discussion 43.

    • Search Google Scholar
    • Export Citation
  • 197.

    Karakiewicz PI, Trinh QD, Rioux-Leclercq N. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol 2007;52:11401145.

    • Search Google Scholar
    • Export Citation
  • 198.

    Gupta R, Billis A, Shah RB. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012;36:12651278.

    • Search Google Scholar
    • Export Citation
  • 199.

    Oudard S, Banu E, Vieillefond A. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007;177:16981702.

    • Search Google Scholar
    • Export Citation
  • 200.

    Fokas E, Henzel M, Hamm K. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol 2010;186:210217.

    • Search Google Scholar
    • Export Citation
  • 201.

    Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379382.

  • 202.

    Schlesinger-Raab A, Treiber U, Zaak D. Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 2008;44:24852495.

    • Search Google Scholar
    • Export Citation
  • 203.

    Roza T, Hakim L, van Poppel H, Joniau S. Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions. Drugs Aging 2013;30:877886.

    • Search Google Scholar
    • Export Citation
  • 204.

    Hunter GK, Balagamwala EH, Koyfman SA. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol 2012;2:e95100.

    • Search Google Scholar
    • Export Citation
  • 205.

    Zelefsky MJ, Greco C, Motzer R. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012;82:17441748.

    • Search Google Scholar
    • Export Citation
  • 206.

    Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962969.

    • Search Google Scholar
    • Export Citation
  • 207.

    Rosen LS, Gordon D, Tchekmedyian NS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:26132621.

    • Search Google Scholar
    • Export Citation
  • 208.

    Henry DH, Costa L, Goldwasser F. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:11251132.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 4226 2325 148
PDF Downloads 1425 970 89
EPUB Downloads 0 0 0